Quarterly vaccination may control blood pressure in future
High blood pressure may soon be treatable with a quarterly vaccination after a Swiss firm reported early success in testing of just such a treatment.
The vaccination, developed by Cytos Biotechnology in Schlieren, Switzerland, significantly reduced blood pressure in a small group of test subjects for up to four months, the company said, adding that there were no serious side effects.
Cytos, reporting its findings in the British medical journal, The Lancet, said it expected that a commercialised version of the vaccine, if proven out in further and larger testing, would need to be administered only three or four times a year.